Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV); Biological
Lead sponsor: Novartis; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 3,604 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Downey, California • Bardstown, Kentucky + 12 more

Conditions: Influenza
Interventions: Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 427 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Miami, Florida • Stockbridge, Georgia • Las Vegas, Nevada + 3 more

Conditions: Seasonal Influenza
Interventions: Planning Prompt, Default Appointment, Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline; Biological · Other
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 3,670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 34
States / cities: Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more

Conditions: Influenza, Human
Interventions: Investigational aQIVc, licensed QIVr, licensed aQIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 7,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 51
States / cities: Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more

Conditions: Influenza
Interventions: Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Respiratory Infection
Interventions: Mindfulness Meditation, Exercise; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 30 Years to 69 Years
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza
Interventions: Influenza A Vaccine: ACAM FLU-A, Saline placebo; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Miami, Florida • Lenexa, Kansas • Tacoma, Washington

Conditions: Influenza
Interventions: A/California/07/09 live monovalent H1N1 vaccine; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 32 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions: Live recombinantly derived A/Bethesda/MM1/H3N2 virus; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adverse Effects in the Therapeutic Use of Interferon
Interventions: interferon gamma 1b; Drug
Lead sponsor: Vidara Therapeutics Research Ltd; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Influenza, Respiratory Tract Infections
Interventions: Portal-based Video Message, Portal-based Infographic Message; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months and older
Enrollment: 22,233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza A H3N2, Influenza A H1N1
Interventions: FLU-IGIV, Placebo for FLU-IGIV; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more

Conditions: Pneumonia, Viral
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Influenza
Interventions: Electronic health record and messaging system; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 84 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine, Quadrivalent Recombinant Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: San Diego, California • Hialeah, Florida • Hollywood, Florida + 8 more

Conditions: Influenza
Interventions: Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 34 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis; Drug · Other · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Placebo, Active Comparator; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more

Conditions: Viral Vaccines
Interventions: Inactivated influenza vaccine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza, Human
Interventions: Procalcitonin, Pharmacist-Led Education; Diagnostic Test · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 49 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Influenza
Interventions: trivalent Influenza vaccine (TIV); Biological
Lead sponsor: Emory University; Other
Eligibility: 25 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Decatur, Georgia

Search by objective public record fields.

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

The Effect of Time-Slot Scheduling on Flu Vaccination Rates

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

University of Wisconsin Meditation & Exercise Cold Study

Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers

Patient Portal Flu Vaccine Reminders (RCT 6)

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Severe Acute Respiratory Infection - Preparedness (COVID-19 and Influenza)

Electronic Health Records for Health Promotion

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Flu Vaccine Responses in the Setting of Melanoma Treatment

Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly